Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
复制标题
DOI：
10.1093/cid/ciw354
复制
发表时间：
2016-08-15
期刊：
影响因子：
--
通讯作者：
Velicer C
中科院分区：
文献类型：
--
作者：
Garland SM;Kjaer SK;Muñoz N;Block SL;Brown DR;DiNubile MJ;Lindsay BR;Kuter BJ;Perez G;Dominiak-Felden G;Saah AJ;Drury R;Das R;Velicer C
这项系统评价评估了四价人乳头瘤病毒 (HPV) 疫苗在现实环境中使用十多年对 HPV 感染和疾病的全球影响和有效性。 HPV 6/11/16/18 感染、肛门生殖器疣和宫颈病变已大幅减少。预防性人乳头瘤病毒 (HPV) 疫苗接种计划构成了全球主要的公共卫生举措。我们评估了四价 HPV (4vHPV) 疫苗接种对 HPV 感染和疾病的总体影响。 PubMed 和 Embase 系统地检索了 2007 年 1 月至 2016 年 2 月期间的同行评审文章，以确定报告 4vHPV 疫苗接种对感染、肛门生殖器疣和宫颈癌或癌前病变的影响或有效性的观察性研究。在过去的十年中，HPV 疫苗接种在现实世界中的影响变得越来越明显，尤其是在疫苗接种率较高的国家中，在接触 HPV 之前接种疫苗的女孩。据报道，HPV 6/11/16/18 感染最大减少约 90%，尖锐湿疣最大减少约 90%，低级别细胞学宫颈异常约最大减少 45%，组织学证实的高级别宫颈异常约最大减少 85%。 HPV 疫苗接种的全部公共卫生潜力尚未实现。 HPV 相关疾病仍然是发展中国家和发达国家发病率和死亡率的重要来源，这凸显了高人口覆盖率的 HPV 疫苗接种计划的必要性。
This systematic review assessed the global impact and effectiveness of quadrivalent human papillomavirus (HPV) vaccination on HPV infection and disease in real-world settings over a decade of use. Substantial reductions in HPV 6/11/16/18 infection, anogenital warts, and cervical lesions have been achieved. Prophylactic human papillomavirus (HPV) vaccination programs constitute major public health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) vaccination on HPV infection and disease. PubMed and Embase were systematically searched for peer-reviewed articles from January 2007 through February 2016 to identify observational studies reporting the impact or effectiveness of 4vHPV vaccination on infection, anogenital warts, and cervical cancer or precancerous lesions. Over the last decade, the impact of HPV vaccination in real-world settings has become increasingly evident, especially among girls vaccinated before HPV exposure in countries with high vaccine uptake. Maximal reductions of approximately 90% for HPV 6/11/16/18 infection, approximately 90% for genital warts, approximately 45% for low-grade cytological cervical abnormalities, and approximately 85% for high-grade histologically proven cervical abnormalities have been reported. The full public health potential of HPV vaccination is not yet realized. HPV-related disease remains a significant source of morbidity and mortality in developing and developed nations, underscoring the need for HPV vaccination programs with high population coverage.